Alexandria Capital’s Standard BioTools LAB Stock Holding History

Alexandria Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.24M	Hold	188,700	–	–	0.12%	137
2021 Q2	$1.16M	Hold	188,700	–	–	0.11%	139
2021 Q1	$853K	Hold	188,700	–	–	0.09%	155
2020 Q4	$1.13M	Hold	188,700	–	–	0.12%	135
2020 Q3	$4.99M	Hold	188,700	–	–	0.6%	58
2020 Q2	$757K	Hold	188,700	–	–	0.1%	149
2020 Q1	$479K	Hold	188,700	–	–	0.08%	162
2019 Q4	$657K	Hold	188,700	–	–	0.09%	154
2019 Q3	$874K	Hold	188,700	–	–	0.13%	141
2019 Q2	$2.33M	Hold	188,700	–	–	0.33%	95
2019 Q1	$2.51M	Hold	188,700	–	–	0.36%	92
2018 Q4	$1.63M	Hold	188,700	–	–	0.26%	109
2018 Q3	$1.41M	Hold	188,700	–	–	0.21%	117
2018 Q2	$1.13M	Hold	188,700	–	–	0.17%	125
2018 Q1	$1.1M	Hold	188,700	–	–	0.16%	129
2017 Q4	$1.11M	Buy	+188,700	New	+$1.03M	0.16%	129

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Alexandria Capital's LAB Position: Q3 2021 in Review

Alexandria Capital held its Standard BioTools (LAB) position steady in Q3 2021 at 188,700 shares worth $1.24M. The position accounts for 0.12% of the portfolio, ranked #137.

Alexandria Capital first reported a position in LAB in Q4 2017 and has held it in 16 quarters since. The position peaked at $4.99M in Q3 2020. 119 funds tracked by Wall St. Rank hold LAB as of Q3 2021.

Alexandria Capital held 188,700 shares of Standard BioTools worth $1.24M as of Q3 2021.
Alexandria Capital left its Standard BioTools share count unchanged in Q3 2021.
Standard BioTools made up 0.12% of Alexandria Capital's portfolio in Q3 2021, its #137 holding.
Alexandria Capital first reported a position in Standard BioTools in Q4 2017 and has held it in 16 quarters since.
Alexandria Capital's Standard BioTools position peaked at $4.99M in Q3 2020.
119 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2021.

Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.